El mercado de la medicina regenerativa se valoró en 11.770 millones de dólares en 2021 y se prevé que llegue a EE. UU. 37.480 millones de dólares para 2031; se espera que crezca a una tasa compuesta anual del 17,9 % entre 2022 y 2031.
La medicina regenerativa es un campo innovador de la medicina que desarrolla métodos para reemplazar/regenerar células, tejidos u órganos humanos para restaurar las funciones normales. Puede curar tejidos u órganos estimulando los mecanismos de reparación del propio cuerpo. La medicina regenerativa permite a los científicos cultivar tejidos y órganos en el laboratorio e implantarlos de forma segura en el cuerpo cuando este no puede curarse a sí mismo.
Adopción creciente de terapias genéticas, terapias con células madre e ingeniería de tejidos; número creciente de aprobaciones para terapias celulares y genéticas; y los avances tecnológicos en el campo de la medicina regenerativa son los factores clave que impulsan el crecimiento del mercado. Sin embargo, el alto coste de estas terapias está obstaculizando la expansión del mercado.
El mercado de la medicina regenerativa se analiza según el tipo, aplicación y geografía. El informe ofrece información y un análisis en profundidad del mercado de la medicina regenerativa, enfatizando varios parámetros como las tendencias del mercado, los avances tecnológicos y la dinámica del mercado, así como el análisis del panorama competitivo de los principales actores del mercado.
Perspectivas estratégicas
regiones lucrativas del mercado de la medicina regenerativa
< h3>Perspectivas del mercado
El creciente número de aprobaciones de terapias celulares y genéticas refuerza el crecimiento del mercado de la medicina regenerativa
Es probable que el creciente número de terapias celulares y genéticas impulse el crecimiento del mercado. Por ejemplo, en mayo de 2022, la Administración de Medicamentos y Alimentos de EE. UU. (FDA) aprobó la terapia con células CAR-T de Novartis Kymriah para pacientes adultos con linfoma folicular (FL) en recaída o refractario (r/r). Kymriah es la primera terapia con células CAR-T aprobada y desarrollada conjuntamente por Novartis y la Facultad de Medicina Perelman de la Universidad de Pensilvania. En febrero de 2022, Janssen Biotech, Inc recibió la aprobación de la FDA de EE. UU. para su CARVYKTI (ciltacabtagene autoleucel; cilta-cel) para tratar adultos con mieloma múltiple en recaída o refractario.
- En agosto de 2022, Bluebird Bio, Inc. recibió la aprobación de la FDA de EE. UU. para su Zynteglo (betibeglogene autotemcel), el primer terapia génica para tratar a pacientes adultos y pediátricos que padecen beta-talasemia y que requieren transfusiones de glóbulos rojos con regularidad.
- En marzo de 2021, la FDA de EE. UU. aprobó Celgene Abecma (idecabtagene vicleucel), una terapia génica basada en células para tratar a pacientes adultos con mieloma múltiple que no han respondido al tratamiento o cuya enfermedad ha recaído incluso después de diferentes tipos de terapias.
Según el tipo, el mercado de la medicina regenerativa se divide en inmunoterapia basada en células y productos de terapia celular, productos de ingeniería de tejidos y productos de terapia génica. La el segmento de productos de inmunoterapia y terapia celular tuvo la mayor participación de mercado en 2021 y se espera que registre la CAGR más alta durante el período de pronóstico.
Mercado de medicina regenerativa, por tipo: 2021 y 2031
Información basada en aplicaciones
Según la aplicación, el mercado de la medicina regenerativa se segmenta en trastornos musculoesqueléticos, cuidado de heridas, oncología, trastornos oculares y diabetes. El segmento de oncología ocupó la mayor cuota de mercado en 2021 y se especula que registrará la mayor CAGR durante 2022-2031.
La pandemia de COVID-19 creó oportunidades de crecimiento para los actores del mercado debido a la urgencia de desarrollar nuevas terapias para los pacientes de COVID-19. Se iniciaron varios proyectos de investigación en la industria de investigación de terapias celulares y génicas. Por ejemplo , en noviembre de 2021, Longeveron Inc. inició su ensayo de fase 1 para probar la seguridad de las células madre mesenquimales (LMSC) de Longeveron en adultos que padecen síndrome de dificultad respiratoria aguda (SDRA) de leve a grave debido a COVID-19.< /p>
En 2022, América del Norte tuvo la mayor participación del mercado de la medicina regenerativa. El crecimiento del mercado se atribuye al aumento de las actividades de investigación y desarrollo en el campo de la medicina regenerativa. Se espera que Asia Pacífico registre el más rápido CAGR durante el período previsto. China, Japón e India son los principales contribuyentes al mercado de la medicina regenerativa en la región. La creciente investigación con células madre, el creciente apoyo gubernamental a la investigación celular y genética y las mejoras en la infraestructura biotecnológica son los factores que impulsan la crecimiento del mercado en APAC.
Por geografía, el mercado de la medicina regenerativa está segmentado en América del Norte (EE. UU., Canadá y México), Europa (Reino Unido, Alemania, Francia, Italia, España y el resto de Europa), Asia Pacífico (China, Japón, India, Corea del Sur, Australia y el resto de Asia Pacífico), Medio Oriente y África (EAU, Arabia Saudita, África y el resto de Medio Oriente y África) y Sur y Centroamérica (Brasil, Argentina y el resto de América Central y del Sur).
Perfiles de la empresa
- Integra LifeSciences
- Gilead Sciences, Inc.
- Novartis AG
- Vericel Corporation
- Wright Medical Group NV
- MiMedx Group
- Osiris Therapeutics, Inc.
- Stryker Corporation
- Spark Therapeutics, Inc.
- Medtronic plc
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Regenerative Medicine Market is expected to register a CAGR of 15.4% from 2023-2031.
The major factors impacting the Regenerative Medicine Market are: Growing Focus on Stem Cell Research, Rising Prevalence of Chronic Diseases, and Advancements in Gene Therapy
Key future trends in this market are - Increase in stem cell research, Adoption of 3D bioprinting, Advances in tissue engineering
Key companies in this market are: Integra LifeSciences Corporation, Gilead Sciences, Novartis, Vericel Corporation, Wright Medical MiMedx, Osiris Therapeutics, Stryker Corporation, Spark Therapeutics
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies
1. Integra LifeSciences Corporation
2. Gilead Sciences
3. Novartis
4. Vericel Corporation
5. Wright Medical
6. MiMedx
7. Osiris Therapeutics
8. Stryker Corporation
9. Spark Therapeutics
10. Medtronic
11. 3M
12. Allergan Plc
13. Aspect Biosystems
14. Bluebird Bio
15. Amgen, Inc.
16. Smith and Nephew Plc
17. Corestem, Inc.
18. Organogenesis
19. Kite Pharma
20. Spark Therapeutics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.